Search Results

You are looking at 71 - 80 of 148 items for :

  • "febrile neutropenia" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Impact of Cumulative Chemotherapy Dose on Survival With Adjuvant FEC-D Chemotherapy for Breast Cancer

Zachary Veitch, Omar F. Khan, Derek Tilley, Patricia A. Tang, Domen Ribnikar, Douglas A. Stewart, Xanthoula Kostaras, Karen King, and Sasha Lupichuk

practices, Shayne et al 30 identified significant predictors of chemotherapy dose reduction, including BSA >2 m 2 , age ≥65 years, febrile neutropenia, and comorbidities (particularly renal disease). In other retrospective studies, obesity has been

Full access

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017

William G. Wierda, Andrew D. Zelenetz, Leo I. Gordon, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, John C. Byrd, Paolo Caimi, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Francisco Hernandez-Ilizaliturri, Richard T. Hoppe, Steven M. Horwitz, Mark S. Kaminski, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Michael G. Martin, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Kenneth Roberts, Ayman A. Saad, Erin D. Snyder, Lubomir Sokol, Lode J. Swinnen, Julie M. Vose, Joachim Yahalom, Mary A. Dwyer, and Hema Sundar

®. P <.001), PFS (not reached in the idelalisib group vs 5.5 months for placebo), and OS at 12 months (92% vs 80%; P =.02) compared with rituximab plus placebo. Grade 3 or 4 AEs (pneumonia, pyrexia, and febrile neutropenia) were reported in 40% of

Full access

New Options for the Management of Castration-Resistant Prostate Cancer: A Case Perspective

Dawn Goetz

seen grade 3 or 4 adverse effects are neutropenia, febrile neutropenia, anemia, leukopenia, diarrhea, fatigue, and asthenia. The approximate neutrophil nadir is 12 days, and cabazitaxel carries a black box warning against giving the drug to patients

Full access

Part 2: Abstracts From the NCCN 18th Annual Conference: Advancing the Standard of Cancer Care™

enrolled at dose level 1 (100 mg, qdx3, weekly), and 2 developed dose-limiting toxicities (DLTs). These DLTs included deep venous thrombosis/pulmonary embolism and grade IV febrile neutropenia in patient 1, and grade III febrile neutropenia and Clostridium

Full access

Who Benefits From Maintenance Therapy in Acute Promyelocytic Leukemia?

Edmond Marzbani and Elihu Estey

, 6 patients were admitted for febrile neutropenia, and 3 cases of nonfatal Pneumocystis jiroveci were seen. 13 , 14 In a Japanese case series of 10 patients, a less-intensive regimen of ATRA, 6-MP, and MTX was used for maintenance, and no patients

Full access

Part 1: Abstracts From the NCCN 18th Annual Conference: Advancing the Standard of Cancer Care™

neutropenia (grade 3: 69%; grade 4: 29%), febrile neutropenia (8%), thrombocytopenia (37%), and anemia (25%). Seven patients experienced treatment-related serious AEs, with 1 grade 5 event. Of the evaluable patients, 80% and 7% achieved clinical complete and

Full access

On the Effect of Triplet or Doublet Chemotherapy in Advanced Gastric Cancer: Results From a National Cancer Registry

Alberto Carmona-Bayonas, Paula Jiménez-Fonseca, Maria Luisa Sánchez Lorenzo, Avinash Ramchandani, Elena Asensio Martínez, Ana Custodio, Marcelo Garrido, Isabel Echavarría, Juana María Cano, Jose Enrique Lorenzo Barreto, Teresa García García, Felipe Álvarez Manceñido, Alejandra Lacalle, Marta Ferrer Cardona, Monserrat Mangas, Laura Visa, Elvira Buxó, Aitor Azkarate, Asunción Díaz-Serrano, Ana Fernández Montes, and Fernando Rivera

overall and grade 3/4 toxicities in comparison with doublets ( Table 3 ), particularly with more grade 3/4 anemia, stomatitis, febrile neutropenia (10.4% vs 6.5%), hepatic toxicity (15.8% vs 9.2%), and toxicity-related hospitalization (30.7% vs 22

Full access

EGFR Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by T790M-Mediated Resistance

Michael Cecchini, Jeffrey Sklar, and Jill Lacy

-line FOLFIRINOX. After 38 weeks, imaging again showed progression of hepatic metastases. He received third-line therapy with docetaxel and irinotecan for 2 weeks, but this therapy was complicated by febrile neutropenia. A tumor specimen from the

Full access

Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology

Erin Reid, Gita Suneja, Richard F. Ambinder, Kevin Ard, Robert Baiocchi, Stefan K. Barta, Evie Carchman, Adam Cohen, Neel Gupta, Kimberly L. Johung, Ann Klopp, Ann S. LaCasce, Chi Lin, Oxana V. Makarova-Rusher, Amitkumar Mehta, Manoj P. Menon, David Morgan, Nitya Nathwani, Ariela Noy, Frank Palella, Lee Ratner, Stacey Rizza, Michelle A. Rudek, Jeff Taylor, Benjamin Tomlinson, Chia-Ching J. Wang, Mary A. Dwyer, and Deborah A. Freedman-Cass

risk. 61 PLWH may be more susceptible to infectious complications after chemotherapy than their uninfected counterparts, 62 and low CD4+ T-cell counts appear to increase the risk of febrile neutropenia. 63 Furthermore, data show that certain

Full access

AIDS-Related Kaposi Sarcoma, Version 2.2019

Erin Reid, Gita Suneja, Richard F. Ambinder, Kevin Ard, Robert Baiocchi, Stefan K. Barta, Evie Carchman, Adam Cohen, Oxana V. Crysler, Neel Gupta, Chelsea Gustafson, Allison Hall, Kimberly L. Johung, Ann Klopp, Ann S. LaCasce, Chi Lin, Amitkumar Mehta, Manoj P. Menon, David Morgan, Nitya Nathwani, Ariela Noy, Lee Ratner, Stacey Rizza, Michelle A. Rudek, Julian Sanchez, Jeff Taylor, Benjamin Tomlinson, Chia-Ching J. Wang, Sai Yendamuri, Mary A. Dwyer, CGC, and Deborah A. Freedman-Cass

uninfected counterparts to infectious complications after chemotherapy, and low CD4+ T-cell counts appear to increase the risk of febrile neutropenia. 47 Furthermore, data show that certain chemotherapy regimens can cause a sustained drop in CD4+ T